Fangsheng Pharmaceutical (603998): Steady dosage of innovative traditional Chinese medicine products to nourish blood, relieve wind and pain, submit marketing applications
Fangsheng Pharmaceutical (603998): The revenue growth rate of 24H1 Ezmeib tablets is impressive, and the volume of the two major new traditional Chinese medicine types is increasing
Fangsheng Pharmaceutical (603998): Focus on innovative traditional Chinese medicine to create beautiful results
Fangsheng Pharmaceutical (603998): Performance exceeded expectations, new products released as scheduled
Fangsheng Pharmaceutical (603998): Changzhong's innovative Chinese medicine giant is about to release new and old products
Fangsheng Pharmaceutical (603998): Nuclear development results are remarkable, innovative research and development is progressing steadily
Fangsheng Pharmaceutical (603998) Company Annual Report Review: Nuclear development results are remarkable, innovation and R&D are progressing steadily
Dongwu Securities released a research report on April 23 stating that it maintains the purchase rating of Fangsheng Pharmaceuticals (603998.SH). The main reasons for the rating include: 1) the steady release of 338 strategic products, and the outstanding
Fangsheng Pharmaceutical (603998): Steady release of strategic products and orderly optimization of the business structure
Fangsheng Pharmaceutical (603998): Focus on innovation in the main business and continue to unleash growth potential
Fangsheng Pharmaceutical (603998): Implementing a “nucleation” development strategy and innovation to drive the continuous growth of the “338” product
Fangsheng Pharmaceutical (603998): Focus on innovative research and development of traditional Chinese medicine “338 Project” to help long-term development
Fangsheng Pharmaceutical (603998): Pharmaceutical manufacturing revenue growth, refined management level improvement
Fangsheng Pharmaceutical (603998) 2023 Third Quarter Report Review Report: Continued Focus on Pharmaceutical Industry Deducting Steady Growth in Non-net Profit
Fangsheng Pharmaceutical (603998): Short-term pressure on the revenue side, Q3 deducts non-profit growth
Fangsheng Pharmaceutical (603998): Business focuses on continuous improvement in the profitability of the pharmaceutical industry sector
Fangsheng Pharmaceutical (603998): Grasping the highland of innovative traditional Chinese medicine and building a foundation for long-term development
Fangsheng Pharmaceutical (603998) 2023 Interim Report Review: Focus on Main Business Development, Clear Endogenous Growth of Big Products, Strong Endogenous Growth
Fangsheng Pharmaceutical (603998): Profit growth is impressive, and after focusing on the main business, the advantages of product clusters continue to be highlighted
Fangsheng Pharmaceutical (603998): 338 products ushered in high growth and continued improvement in profitability
No Data
No Data